Elevated concentrations of lymphocyte-activation gene-3 (LAG-3) and T-cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) in CAR-T infusion samples are correlated with a diminished overall response rate (ORR) of CART19 cell therapy and a heightened probability of early relapse of DLBCL [27]. This evidence concerns the gene LAG3 and diffuse large B-cell lymphoma.